A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.

OBJECTIVE: To determine the current disease-modifying anti-rheumatic drug (DMARD) preferences of UK consultant rheumatologists. METHODS: A questionnaire was sent in May 2002. We asked which DMARD(s) was most frequently preferred first and sought the most typical sequence of DMARDs, including DMARD c...

Bibliográfalaš dieđut
Váldodahkkit:	Jobanputra, P, Wilson, J, Douglas, K, Burls, A
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2004

Geahča maid

A SURVEY OF DMARD PREFERENCES OF UK RHEUMATOLOGISTS
Dahkki: Douglas, K, et al.
Almmustuhtton: (2003)

Doctors’ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
Dahkki: T. Martijn Kuijper, et al.
Almmustuhtton: (2017-04-01)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
Dahkki: Mysler E, et al.
Almmustuhtton: (2021-06-01)

When the first visit to the rheumatologist is established rheumatoid arthritis
Dahkki: Taylor, P, et al.
Almmustuhtton: (2020)

Myocardial infarction in rheumatoid arthritis: The effects of DMARDs and prednisolone
Dahkki: Edwards, C, et al.
Almmustuhtton: (2008)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
Dahkki: Michael D George, et al.
Almmustuhtton: (2021-04-01)

Periodontal Health as Perceived by Rheumatologists and Rheumatoid Arthritis Patients
Dahkki: Natasha Proud, et al.
Almmustuhtton: (2023-04-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
Dahkki: Maria Sergeevna Voronina, et al.
Almmustuhtton: (2012-10-01)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
Dahkki: Kai Wei, et al.
Almmustuhtton: (2022-03-01)

Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
Dahkki: Basant Kumar Maheshwari
Almmustuhtton: (2018-01-01)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation
Dahkki: Jobanputra, P, et al.
Almmustuhtton: (2002)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
Dahkki: Jobanputra, P, et al.
Almmustuhtton: (2002)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation
Dahkki: P. Jobanputra, et al.
Almmustuhtton: (2002-01-01)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
Dahkki: Juthamas Prawjaeng, et al.
Almmustuhtton: (2023-05-01)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
Dahkki: Barton, P, et al.
Almmustuhtton: (2004)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
Dahkki: Barton, P, et al.
Almmustuhtton: (2004)

A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference
Dahkki: Hamre HJ, et al.
Almmustuhtton: (2018-03-01)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis
Dahkki: P Barton, et al.
Almmustuhtton: (2004-03-01)

Elderly-onset rheumatoid arthritis: an outlook from a practicing rheumatologist
Dahkki: Ch. Baimukhamedov
Almmustuhtton: (2020-09-01)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis - Introduction
Dahkki: Barton, P, et al.
Almmustuhtton: (2004)

Patients’ and rheumatologists’ perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis
Dahkki: Laurette van Boheemen, et al.
Almmustuhtton: (2020-09-01)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis
Dahkki: Clark, W, et al.
Almmustuhtton: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
Dahkki: Clark, W, et al.
Almmustuhtton: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
Dahkki: Clark, W, et al.
Almmustuhtton: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis
Dahkki: W Clark, et al.
Almmustuhtton: (2004-09-01)

Individual DMARDs have different effects on the likelihood of developing septic arthritis in adults with rheumatoid arthritis
Dahkki: Edwards, C, et al.
Almmustuhtton: (2005)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
Dahkki: James Cheng-Chung Wei, et al.
Almmustuhtton: (2023-07-01)

Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion
Dahkki: Emiliano Marasco, et al.
Almmustuhtton: (2023-09-01)

Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
Dahkki: Basiru Ahmad Zago, et al.
Almmustuhtton: (2020-12-01)

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope
Dahkki: Tillett, W, et al.
Almmustuhtton: (2020)

Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients
Dahkki: Hazan Karadeniz, et al.
Almmustuhtton: (2022-04-01)

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
Dahkki: Soo-Kyung Cho, et al.
Almmustuhtton: (2017-12-01)

Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis
Dahkki: Esteban A. Gomez, et al.
Almmustuhtton: (2020-10-01)

Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study
Dahkki: Seogsong Jeong, et al.
Almmustuhtton: (2022-07-01)

Challenges in implementing treat-to-target in rheumatoid arthritis: a perspective from Brazilian rheumatologists
Dahkki: Adriana Maria Kakehasi, et al.
Almmustuhtton: (2024-08-01)

Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making
Dahkki: Bolge SC, et al.
Almmustuhtton: (2016-06-01)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Dahkki: Ruiz Garcia, V, et al.
Almmustuhtton: (2014)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Dahkki: Ruiz Garcia, V, et al.
Almmustuhtton: (2011)

To flare or not to flare: patients’ and rheumatologists’ perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis
Dahkki: Delphine Bertrand, et al.
Almmustuhtton: (2024-02-01)

The use of methotrexate in rheumatoid arthritis. Recommendations of the All-Russian public organization “Association of Rheumatologists of Russia”
Dahkki: E. L. Nasonov, et al.
Almmustuhtton: (2023-08-01)